Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomoki Naoe

Showing results (221-230 of 288) with videos related to

Pageof 29
Sort By:
Plos One|March 27, 2014
Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 riskMayumi Imahashi, Taisuke Izumi, Dai Watanabe, et al.
The Journal of Biological Chemistry|February 9, 2013
Mutations in the nucleolar phosphoprotein, nucleophosmin, promote the expression of the oncogenic transcription factor MEF/ELF4 in leukemia cells and potentiates transformationKoji Ando, Hideki Tsushima, Emi Matsuo, et al.
International Journal of Hematology|February 25, 2022
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemiaHiroatsu Iida, Kazunori Imada, Yasunori Ueda, et al.
Plos One|May 9, 2014
Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functionsSatoshi Nishiwaki, Takayuki Nakayama, Makoto Murata, et al.
Blood|March 22, 2007
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 studyNorio Asou, Yuji Kishimoto, Hitoshi Kiyoi, et al.
International Journal of Hematology|January 8, 2010
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 studyShigeki Ohtake, Shuichi Miyawaki, Hitoshi Kiyoi, et al.
Annals of Hematology|January 21, 2014
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcomeNoriyoshi Iriyama, Norio Asou, Yasushi Miyazaki, et al.
Cancer Immunology, Immunotherapy : CII|April 24, 2023
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptideTomoki Naoe, Akiko Saito, Nahoko Hosono, et al.
Cancer Science|February 27, 2016
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugsYoshihiro Hayakawa, Manabu Kawada, Hiroyoshi Nishikawa, et al.
International Journal of Hematology|February 24, 2012
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II studyKensuke Usuki, Arinobu Tojo, Yasuhiro Maeda, et al.
Pageof 29

Showing results (221-230 of 288) with videos related to

Sort By:
Pageof 29
Plos One|March 27, 2014
Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 riskMayumi Imahashi, Taisuke Izumi, Dai Watanabe, et al.
The Journal of Biological Chemistry|February 9, 2013
Mutations in the nucleolar phosphoprotein, nucleophosmin, promote the expression of the oncogenic transcription factor MEF/ELF4 in leukemia cells and potentiates transformationKoji Ando, Hideki Tsushima, Emi Matsuo, et al.
International Journal of Hematology|February 25, 2022
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemiaHiroatsu Iida, Kazunori Imada, Yasunori Ueda, et al.
Plos One|May 9, 2014
Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functionsSatoshi Nishiwaki, Takayuki Nakayama, Makoto Murata, et al.
Blood|March 22, 2007
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 studyNorio Asou, Yuji Kishimoto, Hitoshi Kiyoi, et al.
International Journal of Hematology|January 8, 2010
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 studyShigeki Ohtake, Shuichi Miyawaki, Hitoshi Kiyoi, et al.
Annals of Hematology|January 21, 2014
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcomeNoriyoshi Iriyama, Norio Asou, Yasushi Miyazaki, et al.
Cancer Immunology, Immunotherapy : CII|April 24, 2023
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptideTomoki Naoe, Akiko Saito, Nahoko Hosono, et al.
Cancer Science|February 27, 2016
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugsYoshihiro Hayakawa, Manabu Kawada, Hiroyoshi Nishikawa, et al.
International Journal of Hematology|February 24, 2012
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II studyKensuke Usuki, Arinobu Tojo, Yasuhiro Maeda, et al.
Pageof 29